Coxsackievirus B3 infects the bone marrow and diminishes the restorative capacity of erythroid and lymphoid progenitors

Journal of Virology

Volumn 87, Issue 5, 2013, Pages 2823-2834

  Althof, Nadine ^a   Lindsay Whitton, J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 2; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW; CELL PROLIFERATION; COLONY FORMING UNIT GM; CONTROLLED STUDY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; ERYTHROID PRECURSOR CELL; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; LYMPHOID PROGENITOR CELL; MALE; MOUSE; NEUTROPHIL; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; REGENERATION; RETICULOCYTE; T LYMPHOCYTE; VIRUS GENOME; VIRUS PARTICLE;

ADOPTIVE TRANSFER; ANIMALS; B-LYMPHOCYTES; BLOOD CELL COUNT; BONE MARROW; BONE MARROW CELLS; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; COXSACKIEVIRUS INFECTIONS; CYTOKINES; ENTEROVIRUS B, HUMAN; ERYTHROID PRECURSOR CELLS; HEMATOPOIESIS; LYMPHOCYTE COUNT; LYMPHOID PROGENITOR CELLS; LYMPHOPENIA; MACROPHAGES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; RETICULOCYTES; T-LYMPHOCYTES;

EID: 84874678804     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03004-12     Document Type: Article

References (86)

1. Carthy CM, Yang D, Anderson DR, Wilson JE, McManus BM. 1997. Myocarditis as systemic disease: new perspectives on pathogenesis. Clin. Exp. Pharmacol. Physiol. 24:997-1003.
2. O'Connell JB. 1987. The role of myocarditis in end-stage dilated cardiomyopathy. Tex. Heart Inst. J. 14:268-275.
3. Sole MJ, Liu P. 1993. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J. Am. Coll. Cardiol. 22:99A-105A.
4. Tam PE. 2006. Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol. 19:133-146.
5. Kandolf R, Klingel K, Zell R, Selinka HC, Raab U, Schneider-Brachert W, Bultmann B. 1993. Molecular pathogenesis of enterovirus-induced myocarditis: virus persistence and chronic inflammation. Intervirology 35:140-151.
6. Kandolf R. 1992. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replicatio.n tissue damage, and inflammation. Proc. Natl. Acad. Sci. U. S. A. 89:314-318.
7. Martino TA, Liu P, Sole MJ. 1994. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ. Res. 74:182-188.
8. Mena I, Fischer C, Gebhard JR, Perry CM, Harkins S, Whitton JL. 2000. Coxsackievirus infection of the pancreas: evaluation of receptor expression, pathogenesis, and immunopathology. Virology 271:276-288.
9. Ramsingh AI. 1997. Coxsackieviruses and pancreatitis. Front. Biosci. 2:e53-e62.
10. Palomba E, Tovo PA. 1999. Persistent fever as the only manifestation of chronic coxsackievirus B4 infection in the brain of a human immunodeficiency virus type 1-infected child. Clin. Infect. Dis. 28:912-913.
11. Geller T.J Condie D. 1995. A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin. J. Neurol. Sci. 129:131-133.
12. Hertel NT, Pedersen FK, Heilmann C. 1989. Coxsackie B3 virus encephalitis in a patient with agammaglobulinaemia. Eur. J. Pediatr. 148:642-643
13. Feuer R, Mena I, Pagarigan RR, Harkins S, Hassett DE, Whitton JL. 2003. Coxsackievirus B3 and the neonatal CNS: the roles of stem cells, developing neurons, and apoptosis in infection, viral dissemination, and disease. Am. J. Pathol. 163:1379-1393.
14. Menezes JR, Smith CM, Nelson KC, Luskin MB. 1995. The division of neuronal progenitor cells during migration in the neonatal mammalian forebrain. Mol. Cell Neurosci. 6:496-508.
15. Feuer R, Pagarigan RR, Harkins S, Liu F, Hunziker IP, Whitton JL. 2005. Coxsackievirus targets proliferating neuronal progenitor cells in the neonatal CNS. J. Neurosci. 25:2434-2444.
16. Mercier FE, Ragu C, Scadden DT. 2012. The bone marrow at the crossroads of blood and immunity. Nat. Rev. Immunol. 12:49-60.
17. Zhao E, Xu H, Wang L, Kryczek I, Wu K, Hu Y, Wang G, Zou W. 2012. Bone marrow and the control of immunity. Cell Mol. Immunol. 9:11-19.
18. Baranski B, Armstrong G, Truman JT, Quinnan GV, Jr, Straus SE, Young NS. 1988. Epstein-Barr virus in the bone marrow of patients with aplastic anemia. Ann. Intern. Med. 109:695-704.
19. Shadduck RK, Winkelstein A, Zeigler Z, Lichter J, Goldstein M, Michaels M, Rabin B. 1979. Aplastic anemia following infectious mononucleosis: possible immune etiology. Exp. Hematol. 7:264-271.
20. Apperley JF, Dowding C, Hibbin J, Buiter J, Matutes E, Sissons PJ, Gordon M, Goldman JM. 1989. The effect of cytomegalovirus on hemopoiesis
21. Reddehase MJ, Dreher-Stumpp L, Angele P, Balthesen M, Susa M. 1992. Hematopoietic stem cell deficiency resulting from cytomegalovirus infection of bone marrow stroma. Ann. Hematol. 64
22. Molina JM, Scadden DT, Sakaguchi M, Fuller B, Woon A, Groopman JE. 1990. Lack of evidence for infection of or effect on growth of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus. Blood 76:2476-2482.
23. Young N. 1988. Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin. Hematol. 25:159-172.
24. La Russa VF, Innis BL. 1995. Mechanisms of dengue virus-induced bone marrow suppression. Baillieres Clin. Haematol. 8:249-270.
25. Young NS. 1990. Flaviviruses and bone marrow failure. JAMA 263:3065-3068.
26. Muller U, Steinhoff U, Reis LFL, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264
27. van Houten N, Bouchard PE, Moraska A, Huber SA. 1991. Selection of an attenuated coxsackievirus B3 variant, using a monoclonal antibody reactive to myocyte antigen. J. Virol. 65:1286-1290
28. Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber SA. 1996. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 70:7811-7818.
29. Hunziker IP, Cornell CT, Whitton JL. 2007. Deletions within the 5=UTR of coxsackievirus B3: consequences for virus translation and replication. Virology 360:120-128.
30. Tabor-Godwin JM, Ruller CM, Bagalso N, An N, Pagarigan RR, Harkins S, Gilbert PE, Kiosses WB, Gude NA, Cornell CT, Doran KS, Sussman MA, Whitton JL, Feuer R. 2010. A novel population of myeloid cells responding to coxsackievirus infection assists in the dissemination of virus within the neonatal CNS. J. Neurosci. 30:8676-8691.
31. Ikuta K, Kina T, MacNeil I, Uchida N, Peault B, Chien YH, Weissman IL. 1990. A developmental switch in thymic lymphocyte maturation potential occurs at the level of hematopoietic stem cells. Cell 62:863-874.
32. Kina T, Ikuta K, Takayama E, Wada K, Majumdar AS, Weissman IL, Katsura .Y. 2000. The monoclonal antibody TER-119 recognizes a mole-cule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br. J. Haematol. 109:280-287.
33. Trowbridge IS Lesley J, Schulte R. 1982. Murine cell surface transferrin receptor: studies with an anti-receptor monoclonal antibody. J. Cell. Physiol. 112:403-410.
34. Selin LK, Lin MY, Kraemer KA, Pardoll DM, Schneck JP, Varga SM, Santolucito PA, Pinto AK, Welsh RM. 1999. Attrition of T cell memory: selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 11:733-742
35. McNally JM, Zarozinski CC, Lin MY, Brehm MA, Chen HD, Welsh RM. 2001. Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses. J. Virol. 75:5965-5976
36. McNally JM, Welsh RM. 2002. Bystander T cell activation and attrition. Curr. Top. Microbiol. Immunol. 263:29-41
37. Peacock CD, Kim SK, Welsh RM. 2003. Attrition of virus-specific memory CD8α T cells during reconstitution of lymphopenic environments. J. Immunol. 171:655-663.
38. Welsh RM, Selin LK. 2009. Attrition of memory CD8 T cells. Nature 459:E3-E4
39. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. 2006. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108:3253-3261
40. Furze RC, Rankin SM. 2008. Neutrophil mobilization and clearance in the bone marrow. Immunology 125:281-288
41. Yan XT, Tumpey TM, Kunkel SL, Oakes JE, Lausch RN. 1998. Role of MIP-2 in neutrophil migration and tissue injury in the herpes simplex virus-1-infected cornea. Invest. Ophthalmol. Vis. Sci. 39:1854-1862
42. Lotem J, Sachs L. 2002. Cytokine control of developmental programs in normal hematopoiesis and leukemia. Oncogene 21:3284-3294.
43. Ronnstrand L.2004. Signal transduction via the stem cell factor receptor/ c-Kit. Cell. Mol. Life Sci. 61:2535-2548
44. Buza-Vidas N, Woll P, Hultquist A, Duarte S, Lutteropp M, Bouriez-Jones T, Ferry H, Luc S, Jacobsen SE. 2011. FLT3 expression initiates in fully multipotent mouse hematopoietic progenitor cells. Blood 118:1544-1548.
45. Sitnicka E, Buza-Vidas N, Larsson S, Nygren JM, Liuba K, Jacobsen SE.2003. Human CD34+hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express fltdistinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells Blood 102:881-886.
46. Kikushige Y, Yoshimoto G, Miyamoto T, Iino T, Mori Y, Iwasaki H, Niiro H, Takenaka K, Nagafuji K, Harada M, Ishikawa F, Akashi K. 2008. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J. Immunol. 180:7358-7367.
47. Shurin MR, Esche C, Lotze MT. 1998. FLT3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev. 9:37-48.
48. Chklovskaia E, Jansen W, Nissen C, Lyman SD, Rahner C, Landmann L, Wodnar-Filipowicz A. 1999. Mechanism of flt3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesis. Blood 93:2595-2604.
49. Ruller CM, Tabor-Godwin JM, Van Deren D, Robinson SM, Maciejewski S, Gilbert PE, An N, Gude NA, Sussman MA, Whitton JL, Feuer R. 2012. Neural stem cell depletion following a viral infection leads to CNS developmental defects. Am. J. Pathol. 180:1107-1120
50. Feuer R, Ruller CM, An N, Tabor-Godwin JM, Rhoades RE, Maciejewski S, Pagarigan RR, Cornell CT, Crocker SJ, Kiosses WB, Pham-Mitchell N, Campbell IL, Whitton JL. 2009. Viral persistence and chronic immunopathology in the adult CNS following coxsackievirus infection during the neonatal period. J. Virol. 83:9356-9369.
51. Jarasch-Althof N, Wiesener N, Schmidtke M, Wutzler P, Henke A. 2010. Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19α B lymphocytes. Viral Immunol. 23:369-376
52. Klingel K, McManus BM, Kandolf R. 1995. Enterovirus-infected immune cells of spleen and lymph nodes in the murine model of chronic myocarditis: a role in pathogenesis? Eur. Heart J. 16(Suppl O):42-45.
53. Anderson DR, Wilson JE, Carthy CM, Yang D, Kandolf R, McManus BM. 1996. Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J. Virol. 70:4632-4645
54. Jarasch N, Martin U, Zell R, Wutzler P, Henke A. 2007. Influence of pan-caspase inhibitors on coxsackievirus B3-infected CD19α B lymphocytes. Apoptosis 12:1633-1643
55. Slifka MK, Whitmire JK, Ahmed R. 1997. Bone marrow contains virusspecific cytotoxic T lymphocytes. Blood 90:2103-2108
56. Feuer R, Mena I, Pagarigan RR, Slifka MK, Whitton JL. 2002. Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J. Virol. 76:4430-4440
57. Feuer R, Mena I, Pagarigan RR, Hassett DE, Whitton JL. 2004. Coxsackievirus replication and the cell cycle a potential regulatory mechanism for viral persistence/latency Med. Microbiol. Immunol. (Berl.) 193: 83-90.
58. Whitton JL, Cornell CT, Feuer R. 2005. Host and virus determinants of picornavirus pathogenesis and tropism. Nat. Rev. Microbiol. 3:765-776.
59. Feuer R, Whitton JL. 2008. Preferential coxsackievirus replication in proliferating/activated cells: implications for virus tropism, persistence, and pathogenesis. Curr. Top. Microbiol. Immunol. 149-173.
60. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A. 2009. IFNa activates dormant haematopoietic stem cells in vivo. Nature 458:904-908
61. Wessely .R Klingel K, Knowlton KU, Kandolf R. 2001. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication. Circulation 103: 756-761.
62. Klingel K, Stephan S, Sauter M, Zell R, McManus BM, Bultmann B, Kandolf R. 1996. Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets. J. Virol. 70:8888-8895.
63. Mena I, Perry CM, Harkins S, Rodriguez F, Gebhard JR, Whitton JL. 1999. The role of B lymphocytes in coxsackievirus B3 infection. Am. J. Pathol. 155:1205-1215
64. Vuorinen T, Vainionpaa R, Kettinen H, Hyypia T. 1994. Coxsackievirus B3 infection in human leukocytes and lymphoid cell lines. Blood 84:823-829.
65. Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. 1991. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J. Acquir. Immune. Defic. Syndr. 4:770-776
66. Okada H, Kobune F, Sato TA, Kohama T, Takeuchi Y, Abe T, Takayama N, Tsuchiya T, Tashiro M. 2000. Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients. Arch. Virol. 145:905-920.
67. Wesley A, Coovadia HM, Henderson L. 1978. Immunological recovery after measles. Clin. Exp. Immunol. 32:40-544
68. Schattner A, Meshorer A, Wallach D. 1983. Involvement of interferon in virus-induced lymphopenia. Cell Immunol. 79:11-25.
69. Binder D, Fehr J, Hengartner H, Zinkernagel RM. 1997. Virus-induced transient bone marrow aplasia major role of interferon-a/b during acute infection with the noncytopathic lymphocytic choriomeningitis virus J. Exp. Med. 185:517-530.
70. Swiecki M, Wang Y, Vermi W, Gilfillan S, Schreiber RD, Colonna M. 2011. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J. Exp. Med. 208:2367-2374.
71. Hermesh T, Moltedo B, Moran TM, Lopez CB. 2010. Antiviral instruction of bone marrow leukocytes during respiratory viral infections. Cell Host Microbe 7:343-353
72. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. 2005. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202:637-650
73. Havenar-Daughton C, Kolumam GA, Murali-Krishna K. 2006. Cutting edge the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection J. Immunol. 176:3315-3319.
74. Wetzler M, Talpaz M, Kleinerman ES, King A, Huh YO, Gutterman JU, Kurzrock R. 1990. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am. J. Med. 89:663-672
75. Kawai T, Malech HL. 2009. WHIM syndrome:congenital immune deficiency disease Curr. Opin. Hematol. 16:20-26.
76. Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, Klotman ME, Diaz GA. 2003. Mutations in the chemokine receptor gene CXCR4 are associated withWHIMsyndrome, a combined immunodeficiency disease. Nat. Genet. 34:70-74.
77. Gorlin RJ, Gelb B, Diaz GA, Lofsness KG, Pittelkow MR, Fenyk JR, Jr. 2000.WHIMsyndrome, an autosomal dominant disorder clinical, hematological, and molecular studies Am. J. Med. Genet. 91:368-376.
78. Chow KY, Brotin E, Ben KY, Carthagena L, Teissier S, Danckaert A, Galzi JL, Arenzana-Seisdedos F, Thierry F, Bachelerie F. 2010. A pivotal role for CXCL12 signaling in HPV-mediated transformation of keratinocytes: clues to understanding HPV-pathogenesis in WHIM syndrome. Cell Host Microbe 8:523-533.
79. Tarcan A, Ozbek N, Gurakan B. 2001. Bone marrow failure with concurrent enteroviral infection in a newborn. Pediatr. Infect. Dis. J. 20:719-721
80. Lyman SD, Jacobsen SE. 1998. c-kit ligand and Flt3 ligand: stem/ progenitor cell factors with overlapping yet distinct activities. Blood 91: 1101-1134.
81. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Williams DE, Lyman SD.1996. Hematologic effects of flt3 ligand in vivo in mice. Blood 88:2004-2012
82. Lyman SD, Seaberg M, Hanna R, Zappone J, Brasel K, Abkowitz JL, Prchal JT, Schultz JC, Shahidi NT.1995. Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood 86:4091-4096
83. Wodnar-Filipowicz A, Lyman SD, Gratwohl A, Tichelli A, Speck B, Nissen C. 1996. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood 88:4493-4499.
84. Elian JC, Frappaz D, Pozzetto B, Freycon F. 1993. Transient erythroblastopenia of childhood presenting with echovirus 11 infection. Acta Paediatr. 82:492-494.
85. Vuorinen T, Vainionpaa R, Vanharanta R, Hyypia T. 1996. Susceptibility of human bone marrow cells and hematopoietic cell lines to coxsackievirus B3 infection. J. Virol. 70:9018-9023.
86. Liang DC, Lin KH, Lin DT, Yang CP, Hung KL, Lin KS. 1990. Posthepatitic aplastic anaemia in children in Taiwan, a hepatitis prevalent area. Br. J. Haematol. 74:487-491.